Cymbalta and Neurotoxicity - a phase IV clinical study of FDA data
Summary:
Neurotoxicity is found among people who take Cymbalta, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Cymbalta and have Neurotoxicity. It is created by eHealthMe based on reports of 135,967 people who have side effects when taking Cymbalta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
135,967 people reported to have side effects when taking Cymbalta.
Among them, 12 people (0.01%) have Neurotoxicity.
What is Cymbalta?
Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 145,363 Cymbalta users for its effectiveness, alternative drugs and more.
What is Neurotoxicity?
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system) is found to be associated with 1,157 drugs and 819 conditions by eHealthMe.
Number of Cymbalta and Neurotoxicity reports submitted per year:

Time on Cymbalta when people have Neurotoxicity *:
- < 1 month: 50 %
- 1 - 6 months: 50 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Neurotoxicity when taking Cymbalta *:
- female: 58.33 %
- male: 41.67 %
Age of people who have Neurotoxicity when taking Cymbalta *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 40 %
- 50-59: 30 %
- 60+: 30 %
Common drugs people take besides Cymbalta *:
- Ambien: 4 people, 33.33%
- Lisinopril: 4 people, 33.33%
- Lyrica: 4 people, 33.33%
- Prilosec: 4 people, 33.33%
- Seroquel: 3 people, 25.00%
- Abilify: 2 people, 16.67%
- Klonopin: 2 people, 16.67%
- Isovue-M 200: 2 people, 16.67%
- Neurontin: 2 people, 16.67%
- Flonase: 2 people, 16.67%
Common side effects people have besides Neurotoxicity *:
- Head Injury: 2 people, 16.67%
- Hydrocephalus (water on the brain): 2 people, 16.67%
- Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 2 people, 16.67%
- Confusional State: 2 people, 16.67%
- Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 16.67%
- Hyperhidrosis (abnormally increased sweating): 2 people, 16.67%
- Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 2 people, 16.67%
- Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 2 people, 16.67%
- High Blood Pressure: 2 people, 16.67%
- Meningitis Chemical (chemical exposure causes inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 2 people, 16.67%
Common conditions people have *:
- Spinal Pain (pain in spine): 2 people, 16.67%
- Joint Pain: 2 people, 16.67%
- Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 16.67%
- Anaemia (lack of blood): 1 person, 8.33%
- Anaemia Of Malignant Disease: 1 person, 8.33%
- Bipolar Disorder (mood disorder): 1 person, 8.33%
- Birth Control: 1 person, 8.33%
- Cancer Pain: 1 person, 8.33%
- Constipation: 1 person, 8.33%
- Diabetes: 1 person, 8.33%
* Approximation only. Some reports may have incomplete information.
Do you take Cymbalta and have Neurotoxicity?
Check whether Neurotoxicity is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Neurotoxicity and when was it recovered:
Expand to all the drugs that have ingredients of duloxetine hydrochloride:
Alternative drugs to, pros and cons of Cymbalta:
- Cymbalta (145,363 reports)
Common Cymbalta side effects:
- Fatigue (feeling of tiredness): 13,883 reports
- Dizziness: 13,318 reports
- Headache (pain in head): 11,606 reports
- Pain: 11,210 reports
- Stress and anxiety: 10,457 reports
- Drug ineffective: 10,368 reports
- Insomnia (sleeplessness): 9,690 reports
Browse all side effects of Cymbalta:
a b c d e f g h i j k l m n o p q r s t u v w x y zNeurotoxicity treatments and more:
- Neurotoxicity (13,914 reports)
COVID vaccines that are related to Neurotoxicity:
- Neurotoxicity in Moderna COVID Vaccine
- Neurotoxicity in Pfizer BioNTech Covid Vaccine
- Neurotoxicity in Johnson and Johnson Covid Vaccine
Common drugs associated with Neurotoxicity:
- Cyclophosphamide: 1,548 reports
- Methotrexate: 1,339 reports
- Oxaliplatin: 1,236 reports
- Fludara: 1,025 reports
- Fluorouracil: 984 reports
- Phentermine: 813 reports
- Prednisone: 786 reports
- Cytarabine: 629 reports
- Capecitabine: 606 reports
- Paclitaxel: 559 reports
All the drugs that are associated with Neurotoxicity:
- Neurotoxicity (1,157 drugs)
Common conditions associated with Neurotoxicity:
- Non-hodgkin's lymphoma: 1,068 reports
- Acute lymphocytic leukemia (all): 776 reports
- Chemotherapy: 567 reports
- Herpes zoster: 367 reports
- Hiv infection: 358 reports
- Multiple myeloma: 313 reports
- Colon cancer: 306 reports
- Breast cancer: 278 reports
All the conditions that are associated with Neurotoxicity:
- Neurotoxicity (819 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on duloxetine hydrochloride (the active ingredients of Cymbalta) and Cymbalta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Chapped Lips in Atenolol, how severe and when it was recovered? - 4 seconds ago
- Flaxseed and Sjogren Syndrome - 16 seconds ago
- Lastacaft and Vertigo Aggravated - 44 seconds ago
- Prograf and Mesenteric Vein Thrombosis - 50 seconds ago
- Actos and Enlarged Heart - 56 seconds ago
- Lopurin and Isturisa drug interaction - 58 seconds ago
- Azasite and Blister - 58 seconds ago
- Coenzyme Q10 and Paranasal Sinus Discomfort - a minute ago
- Simethicone and Nisoldipine drug interaction - a minute ago
- Cefzil and Insomnia - a minute ago